Nivolumab for Recurrent or Progressive IDH Mutant Gliomas | MicrobiomeTrials← Back to trialsNCT03557359
Nivolumab for Recurrent or Progressive IDH Mutant Gliomas
CompletedPHASE2INTERVENTIONAL
Trial Details
Start: 2018-06-12Est. Completion: 2022-09-20
Enrollment target: 35 participants Locations- Miami Cancer Center, Miami, Florida, United States
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
- Columbia University Medical Center, New York, New York, United States
- Weill Cornell Medical College, New York, New York, United States
Other microbiome trials you might be interested in
MelanomaNon Small Cell Lung CancerSolid TumorRare CancersHigh Grade Glioma
This study is to provide access for patients who are receiving treatment with dabrafenib and/or trametinib in a Novartis…
Scottsdale, United StatesEst. completion Dec 28, 2032
High Grade GliomaDiffuse Intrinsic Pontine GliomaAnaplastic AstrocytomaGlioblastomaGlioblastoma MultiformeDiffuse Midline Glioma, H3 K27M-Mutant
Metastatic Brain Tumor
WHO Grade III Glioma
WHO Grade IV Glioma
The goal of this study is to perform genetic sequencing on brain tumors from children, adolescents, and young adult pati…
Aurora, United StatesEst. completion Aug 28, 2029
Recurrent Group 3 MedulloblastomaRecurrent Group 4 (Non-SHH/Non-WNT) Medulloblastoma
This is a pilot study in a small number of children and young adults with suspected recurrent/progressive medulloblastom…
Gainesville, United StatesEst. completion Sep 1, 2027